Search
Research
Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal communityWe report the impact on Strongyloides seroprevalence after two oral ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Australian Aboriginal community.
News & Events
Extra whooping cough shot to protect your bubToddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.
The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.
News & Events
Rheumatic heart disease remains a major killer in Oceania regionA new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.
News & Events
Taking on a common respiratory infection in kidsMapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.
News & Events
Childhood influenza vaccination rates improves with better accessMore children across Australia are being vaccinated against the flu since funding was expanded and access widened under the National Immunisation Program
News & Events
Video: Flu vaccine Q&AIt's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.
Research
Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean childrenInvasive pneumococcal disease remains a major cause of hospitalization and death in Papua New Guinean (PNG) children. We assessed mucosal IgA and IgG responses in PNG infants vaccinated with pneumococcal conjugate vaccine (PCV) followed by a pneumococcal polysaccharide vaccine (PPV) booster.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
InfluenzaInfluenza (commonly known as the flu) is caused by a highly contagious virus spread mainly through coughing and sneezing. An annual flu vaccination is the most effective way to prevent flu outbreaks.